INTRODUCTION: Chronic kidney disease (CKD) and atrial fibrillation (AF) often coexist. We studied the association of CKD with atrial fibrosis and the effect of AF ablation on kidney function. METHODS: AF patients who had a pre- and postablation serum creatinine and who completed a late gadolinium enhancement cardiac magnetic resonance imaging (MRI; LGE-MRI) prior to ablation were included. Estimated glomerular filtration rate (eGFR) was calculated and CKD was staged using the National Kidney Foundation guidelines. Patients with eGFR <30 mL/min/1.73 m(2) were excluded. LGE-MRI was used to quantify atrial fibrosis. Patients were followed for recurrence and change in eGFR. RESULTS: A total of 392 patients were included in the study. A total of 118 (30.2%) had CKD stage 1, 198 (50.4%) CKD stage 2, 56 (14.3%) CKD stage 3A, and 20 (5.1%) CKD stage 3B. Patients with advanced CKD were more likely to be male and to have cardiovascular disease. Atrial fibrosis was not significant different between included CKD stages: 15.8 ± 8.8%, 16.6 ± 12.1%, 17.1 ± 10.4%, and 16.5 ± 8.4% for CKD stage 1, 2, 3A, and 3B, respectively (P = 0.476). At a median of 115 days following ablation, eGFR increased significantly in CKD stage 2 (74 ± 9 to 80 ± 23; P = 0.04), 3A (53 ± 5 to 69 ± 24; P < 0.001), and 3B (40 ± 4 to 71 ± 28; P < 0.01) and decreased in CKD stage 1 (109 ± 18 to 82 ± 28; P < 0.001). Arrhythmia recurrence was associated with atrial fibrosis (hazard ratio [HR] = 1.04, P < 0.01) and persistent AF (HR = 1.5; P = 0.04) but not with CKD stage (HR = 0.98; P = 0.89). CONCLUSIONS: Restoring sinus rhythm with ablation leads to significant improvement of renal function in patients with chronic kidney disease.
INTRODUCTION:Chronic kidney disease (CKD) and atrial fibrillation (AF) often coexist. We studied the association of CKD with atrial fibrosis and the effect of AF ablation on kidney function. METHODS:AFpatients who had a pre- and postablation serum creatinine and who completed a late gadolinium enhancement cardiac magnetic resonance imaging (MRI; LGE-MRI) prior to ablation were included. Estimated glomerular filtration rate (eGFR) was calculated and CKD was staged using the National Kidney Foundation guidelines. Patients with eGFR <30 mL/min/1.73 m(2) were excluded. LGE-MRI was used to quantify atrial fibrosis. Patients were followed for recurrence and change in eGFR. RESULTS: A total of 392 patients were included in the study. A total of 118 (30.2%) had CKD stage 1, 198 (50.4%) CKD stage 2, 56 (14.3%) CKD stage 3A, and 20 (5.1%) CKD stage 3B. Patients with advanced CKD were more likely to be male and to have cardiovascular disease. Atrial fibrosis was not significant different between included CKD stages: 15.8 ± 8.8%, 16.6 ± 12.1%, 17.1 ± 10.4%, and 16.5 ± 8.4% for CKD stage 1, 2, 3A, and 3B, respectively (P = 0.476). At a median of 115 days following ablation, eGFR increased significantly in CKD stage 2 (74 ± 9 to 80 ± 23; P = 0.04), 3A (53 ± 5 to 69 ± 24; P < 0.001), and 3B (40 ± 4 to 71 ± 28; P < 0.01) and decreased in CKD stage 1 (109 ± 18 to 82 ± 28; P < 0.001). Arrhythmia recurrence was associated with atrial fibrosis (hazard ratio [HR] = 1.04, P < 0.01) and persistent AF (HR = 1.5; P = 0.04) but not with CKD stage (HR = 0.98; P = 0.89). CONCLUSIONS: Restoring sinus rhythm with ablation leads to significant improvement of renal function in patients with chronic kidney disease.
Authors: Shingo Maeda; William W Chik; Jackson J Liang; Iosif Kelesidis; Ruben Casado Arroyo; Benjamin D'Souza; Mouhannad M Sadek; Daniele Muser; Fabien Squara; Deviprasad Venugopal; Pasquale Santangeli; David S Frankel; Erica S Zado; Francis E Marchlinski; David J Callans Journal: J Interv Card Electrophysiol Date: 2016-10-10 Impact factor: 1.900
Authors: Monika Kozieł; Stefan Simovic; Nikola Pavlovic; Milan Nedeljkovic; Aleksandar Kocijancic; Vilma Paparisto; Ljilja Music; Elina Trendafilova; Anca Rodica Dan; Sime Manola; Zumreta Kusljugic; Gheorghe-Andrei Dan; Gregory Y H Lip; Tatjana S Potpara Journal: J Arrhythm Date: 2020-07-19
Authors: Nisha Bansal; Dawei Xie; Kelvin Tao; Jing Chen; Rajat Deo; Edward Horwitz; Chi-Yuan Hsu; Radha Krishna Kallem; Martin G Keane; Claudia M Lora; Dominic Raj; Elsayed Z Soliman; Louise Strauss; Myles Wolf; Alan S Go Journal: Clin J Am Soc Nephrol Date: 2016-04-12 Impact factor: 8.237
Authors: Giuseppe Boriani; Irina Savelieva; Gheorghe-Andrei Dan; Jean Claude Deharo; Charles Ferro; Carsten W Israel; Deirdre A Lane; Gaetano La Manna; Joseph Morton; Angel Moya Mitjans; Marc A Vos; Mintu P Turakhia; Gregory Y H Lip Journal: Europace Date: 2015-06-24 Impact factor: 5.214
Authors: Celso L Diaz; Rachel M Kaplan; Graham Peigh; Aakash Bavishi; Jayson R Baman; Amar Trivedi; Mark J Shen; Prasongchai Sattayaprasert; Jeremiah Wasserlauf; Rishi Arora; Alexandru B Chicos; Susan Kim; Albert Lin; Nishant Verma; Bradley P Knight; Rod S Passman Journal: J Interv Card Electrophysiol Date: 2020-05-15 Impact factor: 1.759
Authors: K Sattler; M Behnes; C Barth; A Wenke; B Sartorius; I El-Battrawy; K Mashayekhi; J Kuschyk; U Hoffmann; T Papavasiliu; C Fastner; S Baumann; S Lang; X Zhou; G Yücel; M Borggrefe; I Akin Journal: Metabolomics Date: 2017-09-20 Impact factor: 4.290